Cited 20 times in
A phase I/II and pharmacogenomic study of pemetrexed and cisplatin in patients with unresectable, advanced gastric carcinoma.
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 정현철 | - |
dc.date.accessioned | 2015-04-23T16:52:52Z | - |
dc.date.available | 2015-04-23T16:52:52Z | - |
dc.date.issued | 2010 | - |
dc.identifier.issn | 0959-4973 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/101404 | - |
dc.description.abstract | This phase I/II study was conducted to determine the maximum recommended dose of pemetrexed when given in combination with a fixed dose of cisplatin, and the efficacy, toxicity and association of 5,10-methylenetetrahydrofolate reductase (MTHFR) variants with this pemetrexed--cisplatin combination, in patients with unresectable, advanced gastric carcinoma. Patients 18-70 years of age, with stage IV disease or post-surgery recurrence, no earlier palliative chemotherapy, 0 or 1 Eastern Cooperative Oncology Group performance status, were included. The cisplatin dose was 75 mg/m. In phase I, the initial dose of pemetrexed was 600 mg/m, escalated in 100 mg/m increments. In phase II, efficacy, including overall response rate, overall survival, as well as toxicity and MTHFR pharmacogenetics were investigated. Phase I enrolled 16 patients; 700 mg/m was defined as pemetrexed recommended dose. Thirteen serious adverse events were reported; the most common grade 3/4 toxicities were haematologic (10 of 13, 76.9%). Phase II enrolled 73 patients, 69 qualified for safety and 68 for efficacy analysis; 65 for pharmacogenomic analysis. Overall response rate was 23.5% (14.1%, 35.4%), disease control rate 55.9%, median overall survival 11.8 months (95% confidence interval, 7.2-18.5 months), progression-free survival 4.9 months (95% confidence interval, 2.8-7.1 months), and median response duration 5.4 months. Patients with MTHFR A1298C variants had median overall survival of 6.6 months, significantly shorter than patients with the wild type (median 18.5 months, P=0.001). The pemetrexed--cisplatin combination in patients with advanced gastric cancer generates modest efficacy and a manageable toxicity profile. The reduced overall survival in patients with MTHFR A1298C polymorphism variants deserves further investigation | - |
dc.description.statementOfResponsibility | open | - |
dc.format.extent | 777~784 | - |
dc.relation.isPartOf | ANTI-CANCER DRUGS | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.rights.uri | https://creativecommons.org/licenses/by-nc-nd/2.0/kr/ | - |
dc.subject.MESH | Adult | - |
dc.subject.MESH | Aged | - |
dc.subject.MESH | Antineoplastic Combined Chemotherapy Protocols/adverse effects | - |
dc.subject.MESH | Antineoplastic Combined Chemotherapy Protocols/pharmacology | - |
dc.subject.MESH | Antineoplastic Combined Chemotherapy Protocols/therapeutic use* | - |
dc.subject.MESH | Cisplatin/adverse effects | - |
dc.subject.MESH | Cisplatin/pharmacology | - |
dc.subject.MESH | Cisplatin/therapeutic use* | - |
dc.subject.MESH | Female | - |
dc.subject.MESH | Folic Acid Antagonists/administration & dosage | - |
dc.subject.MESH | Folic Acid Antagonists/adverse effects | - |
dc.subject.MESH | Folic Acid Antagonists/pharmacology | - |
dc.subject.MESH | Glutamates/adverse effects | - |
dc.subject.MESH | Glutamates/pharmacology | - |
dc.subject.MESH | Glutamates/therapeutic use* | - |
dc.subject.MESH | Guanine/adverse effects | - |
dc.subject.MESH | Guanine/analogs & derivatives* | - |
dc.subject.MESH | Guanine/pharmacology | - |
dc.subject.MESH | Guanine/therapeutic use | - |
dc.subject.MESH | Humans | - |
dc.subject.MESH | Male | - |
dc.subject.MESH | Membrane Transport Proteins/genetics | - |
dc.subject.MESH | Methylenetetrahydrofolate Reductase (NADPH2)/genetics | - |
dc.subject.MESH | Middle Aged | - |
dc.subject.MESH | Pemetrexed | - |
dc.subject.MESH | Pharmacogenetics | - |
dc.subject.MESH | Stomach Neoplasms/drug therapy* | - |
dc.subject.MESH | Stomach Neoplasms/genetics | - |
dc.subject.MESH | Stomach Neoplasms/metabolism | - |
dc.subject.MESH | Survival Analysis | - |
dc.subject.MESH | Treatment Outcome | - |
dc.subject.MESH | Young Adult | - |
dc.title | A phase I/II and pharmacogenomic study of pemetrexed and cisplatin in patients with unresectable, advanced gastric carcinoma. | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine (의과대학) | - |
dc.contributor.department | Dept. of Internal Medicine (내과학) | - |
dc.contributor.googleauthor | Jen-Shi Chen | - |
dc.contributor.googleauthor | Yee Chao | - |
dc.contributor.googleauthor | Yung-Jue Bang | - |
dc.contributor.googleauthor | Enrique Roca | - |
dc.contributor.googleauthor | Hyun C. Chung | - |
dc.contributor.googleauthor | Felipe Palazzo | - |
dc.contributor.googleauthor | Yeul H. Kim | - |
dc.contributor.googleauthor | Scott P. Myrand | - |
dc.contributor.googleauthor | Brian P. Mullaney | - |
dc.contributor.googleauthor | Li J. Shen | - |
dc.contributor.googleauthor | Carlos Linn | - |
dc.identifier.doi | 10.1097/CAD.0b013e32833cfbca | - |
dc.admin.author | false | - |
dc.admin.mapping | false | - |
dc.contributor.localId | A03773 | - |
dc.relation.journalcode | J00187 | - |
dc.identifier.eissn | 1473-5741 | - |
dc.identifier.pmid | 20634689 | - |
dc.identifier.url | http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&AN=00001813-201009000-00007&LSLINK=80&D=ovft | - |
dc.subject.keyword | advanced gastric carcinoma | - |
dc.subject.keyword | cisplatin | - |
dc.subject.keyword | MTHFR | - |
dc.subject.keyword | pharmacogenetics | - |
dc.subject.keyword | phase I/II clinical trials | - |
dc.subject.keyword | pemetrexed | - |
dc.subject.keyword | unresectable | - |
dc.contributor.alternativeName | Chung, Hyun Cheol | - |
dc.contributor.affiliatedAuthor | Chung, Hyun Cheol | - |
dc.citation.volume | 21 | - |
dc.citation.number | 8 | - |
dc.citation.startPage | 777 | - |
dc.citation.endPage | 784 | - |
dc.identifier.bibliographicCitation | ANTI-CANCER DRUGS, Vol.21(8) : 777-784, 2010 | - |
dc.identifier.rimsid | 51034 | - |
dc.type.rims | ART | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.